➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Express Scripts
Medtronic
Boehringer Ingelheim
Moodys

Last Updated: September 18, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,672,583

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,672,583
Title: Carboxy-peptidyl derivatives as antidegenerative active agents
Abstract:Novel Carboxy-peptidyl compounds of Formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, coronary thrombosis associated with atherosclerotic plaque rupture, and aneurysmal aortic disease. The matrix metalloendoproteinases are a family of zinc-containing proteinases including but not limited to stromelysin, collagenase, and gelatinase, that are capable of degrading the major components of articular cartilage and basement membranes. The inhibitors claimed herein may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to a permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation. ##STR1##
Inventor(s): Chapman; Kevin (Scotch Plains, NJ), Hagmann; William (Westfield, NJ), Durette; Philippe (New Providence, NJ), Esser; Craig (Belford, NJ), Kopka; Ihor (Millburn, NJ), Caldwell; Charles (Scotch Plains, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/436,347
Patent Claims:1. A compound of Formula I ##STR79## or a pharmaceutically acceptable salt thereof wherein: Y is --CH.sub.2 --, CH(C.sub.1-3 alkyl);

R.sub.1 is mono- or di-substituted C.sub.1-6 alkyl, wherein the substituents are independently selected from the group consisting of:

(a) hydrogen,

(b) aryl group selected from the group consisting of:

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carboxazolyl,

(23) isoxazolyl,

(24) thiazolyl,

(25) oxazolyl,

(26) benzthiazolyl, and

(27) benzoxazolyl,

which can be mono- or di-substituted with substitutents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, halo, hydroxy, amino, C.sub.1-6 alkylamino, aminoC.sub.1-6 alkyl, carboxyl, carboxylC.sub.1-6 alkyl, or C.sub.1-6 alkylcarbonyl;

R.sub.2 is arylC.sub.1-4 alkyl or aryl substituted C.sub.1-4 alkyl or biaryl C.sub.1-4 alkyl wherein the substituent is C.sub.1-3 alkyl, and wherein the aryl group is selected from the group consisting of:

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carboxazolyl,

(23) isoxazolyl,

(24) thiazolyl,

(25) oxazolyl,

(26) benzthiazolyl, and

(27) benzoxazolyl,

and mono and di-substituted aryl as defined above in items (1) to (27) wherein the substitutents on the aryl group are independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkoxyC.sub.1-6 alkyl, halo, hydroxy, amino, C.sub.1-6 alkylamino, aminoC.sub.1-6 alkyl, carboxyl, carboxylC.sub.1-6 alkyl, and C.sub.1-6 alkylcarbonyl;

R.sub.3 is

(a) H,

(b) Z, where Z is a pharmaceutically acceptable counterion,

(c) C.sub.1-10 alkyl,

(d) aryl or aryl C.sub.1-3 alkyl, wherein the aryl group is selected from the group consisting of

(1) phenyl, and

(2) substituted phenyl, wherein the substitutents is carboxy, carboxyC.sub.1-3 alkyl, aminocarbonyl, C.sub.1-6 alkylaminocarbonyl;

AA is an amino acid of formula II ##STR80## wherein R.sub.f and R.sub.g are individually selected from: (a) hydrogen,

(b) C.sub.1-6 alkyl,

(c) mercapto C.sub.1-6 alkyl,

(d) hydroxy C.sub.1-6 alkyl,

(e) carboxy C.sub.1-6 alkyl,

(f) amino substituted C.sub.2-6 alkyl

(g) aminocarbonyl C.sub.1-6 alkyl,

(h) mono- or di-C.sub.1-6 alkyl amino C.sub.2-6 alkyl,

(i) guanidino C.sub.2-6 alkyl,

(j) substituted phenyl C.sub.1-6 alkyl, wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(k) substituted indolyl C.sub.1-6 alkyl, wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(l) substituted imidazolyl C.sub.2-6 alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(m) substituted pyridyl C.sub.1-6 alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(n) substituted pyridylamino C.sub.1-6 alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(o) substituted pyrimidinyl C.sub.1-6 alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

X is ##STR81## wherein R.sub.5 and R.sub.6 are each individually selected from the group consisting of:

(a) H,

(c) Aryl or ArylC.sub.1-6 alkyl, wherein the aryl group is selected from the group consisting of

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carbazolyl,

(23) isoxazolyl,

(24) benzthiazolyl,

(25) benzoxazolyl,

(26) thiazolyl, and

(27) oxazolyl

and mono and di-substituted Aryl as defined above in items (1) to (27) wherein the substitutents are independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkoxyC.sub.1-6 alkyl, halo, hydroxy, amino, C.sub.1-6 alkylamino, aminoC.sub.1-6 alkyl, carboxyl, carboxylC.sub.1-6 alkyl, and C.sub.1-6 alkylcarbonyl.

2. A compound according to claim 1 wherein:

R.sub.2 is arylC.sub.1-4 alkyl, or biarylC.sub.1-4 alkyl wherein the aryl group is selected from the group consisting of:

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carboxazolyl,

(23) isoxazolyl,

(24) thiazolyl,

(25) oxazolyl,

(26) benzthiazolyl, and

(27) benzoxazolyl,

and mono and di-substituted aryl as defined above in items (1) to (27) wherein the substitutents are independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, halo, hydroxy, amino, C.sub.1-6 alkylamino, aminoC.sub.1-6 alkyl, carboxyl, carboxylC.sub.1-6 alkyl, and C.sub.1-6 alkylcarbonyl.

3. A compound according to claim 2 wherein:

R.sub.1 is substituted C.sub.1-6 alkyl, wherein the substituent is selected from the group consisting of:

(a) hydrogen,

(b) Aryl wherein the aryl group is selected from the group consisting of

(1) phenyl,

(2) naphthyl,

(3) thienyl,

(4) imidazolyl,

(5) benzimidazolyl,

(6) pyrimidyl,

(7) benzofuryl,

(8 ) benzothienyl, and

(9) indolyl;

and mono and di-substituted Aryl as defined above in items (1) to (9) wherein the substitutents are independently selected from C.sub.1-6 alkyl, C.sub.1-3 alkyloxy, halo, hydroxy, amino, C.sub.1-3 alkylamino, aminoC.sub.1-3 alkyl, carboxyl, carboxylC.sub.1-3 alkyl, and C.sub.1-3 alkylcarbonyl.

4. A compound according to claim 3 wherein:

R.sub.3 is

(a) H,

(b) Z,

(c) C.sub.1-4 alkyl,

(d) phenyl, substituted phenyl, wherein the substitutent is carboxy, carboxy C.sub.1-3 alkyl, amino carbonyl.

5. A compound according to claim 3 wherein:

AA is an amino acid selected from glycine, alanine, valine, leucine, isoleucine, 2-tert-butyl-glycine, penicilliamine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxy-lysine, homohistidine, arginine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, ornithine, homoserine and citrulline.

6. A compound according to claim 4 wherein:

the substituents are selected from:

(a) hydrogen,

(b) C.sub.1-4 alkyl,

(c) mercapto C.sub.1-3 alkyl,

(d) hydroxy C.sub.1-4 alkyl,

(e) carboxy C.sub.1-4 alkyl,

(f) amino C.sub.1-4 alkyl,

(g) aminocarbonyl C.sub.1-4 alkyl,

(h) mono- or di-C.sub.1-4 alkyl amino C.sub.1-4 alkyl,

(i) guanidino C.sub.1-4 alkyl,

(j) substituted phenyl C.sub.1-4 alkyl, wherein the substituent is hydrogen, hydroxy, carboxy, or C.sub.1-3 alkyl,

(k) substituted indolyl C.sub.1-4 alkyl, wherein the substituent is hydrogen, hydroxy, carboxy, or C.sub.1-3 alkyl,

(l) substituted imidazolyl C.sub.2-4 alkyl wherein the substituent is hydrogen, hydroxy, carboxy, or C.sub.1-4 alkyl.

7. A compound according to claim 6 wherein:

X is ##STR82## wherein R.sub.5 and R.sub.6 are each individually selected from the group consisting of:

(a) H,

(b) Aryl or ArylC.sub.1-4 alkyl, wherein the aryl group is selected from the group consisting of

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) thienyl,

(5) imidazolyl,

(6) tetrazolyl,

(7) pyrazinyl,

(8) pyrimidyl,

(9) benzofuryl,

(10) benzothienyl,

(11) pyrazolyl, and

(12) indolyl,

and mono and di-substituted Aryl as defined above in items (1) to (12) wherein the substitutents are independently selected from C.sub.1-3 alkyl, C.sub.1-3 alkyloxy, halo, hydroxy, amino, C.sub.1-3 alkylamino, aminoC.sub.1-3 alkyl, carboxyl, carboxylC.sub.1-3 alkyl, and C.sub.1-3 alkylcarbonyl.

8. A compound according to claim 7 wherein

Y is --CH.sub.2 --

R.sub.1 is hydrogen, substituted C.sub.1-4 alkyl or substituted C.sub.2-4 alkenyl wherein the substituent is hydrogen, and Aryl wherein the aryl is selected from the group consisting of

R.sub.2 is arylC.sub.1-4 alkyl, or biarylC.sub.1-4 alkyl wherein the aryl group is is selected from the group consisting of phenyl, thienyl, pyridyl, or naphthyl;

R.sub.3 is

(a) H, or

(b) Z;

R.sub.f is H;

R.sub.g is

(a) hydrogen;

(b) C.sub.1-6 alkyl; or

(c) guanidino C.sub.1-6 alkyl

R.sub.5 is H; and

R.sub.6 is Aryl or monosubstitued aryl, wherein the aryl is phenyl and the substituent is selected from C.sub.1-8 alkyl, halo, and hydroxy

R.sub.b is H.

9. A compound according to claim 7 wherein ##STR83##

10. A pharmaceutical composition for treating a matrix metalloendoproteinase-mediated disease comprising a pharmaceutical carrier and a non-toxic effective amount of the compound of claim 1.

11. A method for inhibiting the lytic activity of metalloendoproteinases comprising administering to a subject suffering from matrix metalloendoproteinase mediated disease, and inhibitory amount of the compound of claim 1.

12. A method according to claim 11 in which the metalloendoproteinase is stromelysin.

13. A method according to claim 11 in which the metalloendoproteinase is collagenase.

14. A method according to claim 11 in which the metalloendoproteinase is gelatinase.

15. A method for inhibiting the activity of stromelysin comprising administering to a subject suffering from a stromelysin mediated disease, a therapeutic amount of the compound of claim 1.

16. A method according to claim 15 wherein the stromelysin inhibitor is administered in an amount of from about 0.01 to 50 mg of the compound per kilogram body weight.

17. A method of treating matrix metalloendo-proteinase-mediated disease comprising the administration to a subject in need of such a therapeutically effective amount of a compound claim 1.

18. A compound of Formula I ##STR84## or a pharmaceutically acceptable salt thereof wherein: Y is --CH.sub.2 -- CH(C.sub.1-3 alkyl);

R.sub.1 is mono- or di-substituted C.sub.1-6 alkyl, wherein the substituents are independently selected from the group consisting of:

(a) hydrogen,

(b) aryl group selected from the group consisting of:

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carboxazolyl,

(23) isoxazolyl,

(24) thiazolyl,

(25) oxazolyl,

(26) benzthiazolyl, and

(27) benzoxazolyl,

which can be mono- or di-substituted with substitutents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, halo, hydroxy, amino, C.sub.1-6 alkylamino, aminoC.sub.1-6 alkyl, carboxyl, carboxylC.sub.1-6 alkyl, or C.sub.1-6 alkylcarbonyl,;

R.sub.2 is arylC.sub.1-4 alkyl or aryl substituted C.sub.1-4 alkyl or biaryl C.sub.1-4 alkyl wherein the substituent is C.sub.1-3 alkyl, and wherein the aryl group is selected from the group consisting of:

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carboxazolyl,

(23) isoxazolyl,

(24) thiazolyl,

(25) oxazolyl,

(26) benzthiazolyl, and

(27) benzoxazolyl,

and mono and di-substituted aryl as defined above in items (1) to (27) wherein the substitutents on the aryl group are independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkoxyC.sub.1-6 alkyl, halo, hydroxy, amino, C.sub.1-6 alkylamino, aminoC.sub.1-6 alkyl, carboxyl, carboxylC.sub.1-6 alkyl, and C.sub.1-6 alkylcarbonyl;

R.sub.3 is

(a) H,

(b) Z, where Z is a pharmaceutically acceptable counterion,

(c) C.sub.1-10 alkyl,

(d) aryl or aryl C.sub.1-3 alkyl, wherein the aryl group is selected from the group consisting of

(1) phenyl, and

(2) substituted phenyl, wherein the substitutent is carboxy, carboxyC.sub.1-3 alkyl, aminocarbonyl, C.sub.1-6 alkylaminocarbonyl;

AA is an amino acid of formula II ##STR85## wherein R.sub.f and R.sub.g are individually selected from: (a) hydrogen,

(b) C.sub.1-6 alkyl,

(c) mercapto C.sub.1-6 alkyl,

(d) hydroxy C.sub.1-6 alkyl,

(e) carboxy C.sub.1-6 alkyl,

(f) amino substituted C.sub.2-6 alkyl

(g) aminocarbonyl C.sub.1-6 alkyl,

(h) mono- or di-C.sub.1-6 alkyl amino C.sub.2-6 alkyl,

(i) guanidino C.sub.2-6 alkyl,

(j) substituted phenyl C.sub.1-6 alkyl, wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(k) substituted indolyl C.sub.1-6 alkyl, wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(l) substituted imidazolyl C.sub.2-6 alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(m) substituted pyridyl C.sub.1-6 alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(n) substituted pyridylamino C.sub.1-6 alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(o) substituted pyrimidinyl C.sub.1-6 alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

X is ##STR86## wherein R.sub.5 is Aryl or ArylC.sub.1-6 alkyl, wherein the aryl group is selected from the group consisting of

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carbazolyl,

(23) isoxazolyl,

(24) benzthiazolyl,

(25) benzoxazolyl,

(26) thiazolyl, and

(27) oxazolyl

and mono and di-substituted Aryl as defined above in items (1) to (27) wherein the substitutents are independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkoxyC.sub.1-6 alkyl, halo, hydroxy, amino, C.sub.1-6 alkylamino, aminoC.sub.1-6 alkyl, carboxyl, carboxylC.sub.1-6 alkyl, and C.sub.1-6 alkylcarbonyl; and

R.sub.6 is

(a) H,

(b) C.sub.1-10 alkyl,

(c) Aryl or ArylC.sub.1-6 alkyl, wherein the aryl group is selected from the group consisting of

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carbazolyl,

(23) isoxazolyl,

(24) benzthiazolyl,

(25) benzoxazolyl,

(26) thiazolyl, and

(27) oxazolyl

and mono and di-substituted Aryl as defined above in items (1) to (27) wherein the substitutents are independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkoxyC.sub.1-6 alkyl, halo, hydroxy, amino, C.sub.1-6 alkylamino, aminoC.sub.1-6 alkyl, carboxyl, carboxylC.sub.1-6 alkyl, and C.sub.1-6 alkylcarbonyl.

19. A compound

a) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-1,5-pentanedioic acid 1-(L-leucine, N-phenylamide)amide,

b) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-1,5-pentanedioic acid 1-(2(S)-t-butyl)glycine, N-phenylamide)amide,

c) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-1,5-pentanedioic acid 1-(2(S)-t-butyl)glycine, N-(4-pyridyl)amide)amide,

d) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-1,5-pentanedioic acid 1-(L-arginine, N-methylamide)amide,

e) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-methyl-1,5-pentanedioic acid 1-(L-leucine, N-phenylamide)amide,

f) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-methyl-1,5-pentanedioic acid 1-(2(S)-t-butyl)glycine, N-phenylamide)amide,

g) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-methyl-1,5-pentanedioic acid 1-(L-leucine, N-(4-pyridyl)amide)amide,

h) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-methyl-1,5-pentanedioic acid 1-(L-arginine, N-phenylamide)amide,

i) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-methyl-1,5-pentanedioic acid 1-(L-phenylalanine, N-4-pyridyl)amide)amide,

j) 2(R)-(2-(4-(4-fluorophenyl)phenyl)ethyl)-4-methyl-1,5-pentanedioic acid 1-(L-leucine, N-phenylamide)amide,

k) 2(R)-(2-(4-(phenyl)phenyl)ethyl)-4-methyl-1,5-pentanedioic acid 1-(L-leucine, N-phenylamide)amide,

l) 2(R)-(2-(4-(4-methoxyphenyl)phenyl)ethyl)-4-methyl-1,5-pentanedioic acid 1-(L-leucine phenylamide)amide,

m) 2(R)-(2-(4-(4-methylphenyl)phenyl)ethyl)-4-methyl-1,5-pentanedioic acid 1-(L-leucine phenylamide)amide,

n) 2(R)-(2-(4-(4-hydroxy-n-butyl)-phenyl)-ethyl)-4-methylpentanedioic acid 1-(S-leucine phenylamide) amide,

n) 2(R),4(S)-(2-(4-(3-hydroxy-n-propyl)phenyl)ethyl)-4-methyl-1,5-pentanedioi c acid 1-(L-leucine, N-phenylamide)amide,

o) 2(R)-(2-phenylethyl)-4-methyl-1,5-pentanedioic acid 1-(L-leucine, N-phenylamide)amide,

p) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-1,5-pentanedioic acid 1-(L-leucine, N-ethylamide)amide,

q) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-1,5-pentanedioic acid 1-(L-leucine, N-isopropylamide)amide,

r) 2(R)-(2-(4-(1-n-Propyl)phenyl)propyl)-1,5-pentanedioic acid 1-(2(S)-tert-butyl-glycine, N-(4-pyridyl)amide)amide,

s) 2(R)-(3-(4-(1-n-Propyl)phenyl)propyl)-1,3-pentanedioic acid 1-(L-leucine, N-phenylamide)amide,

t) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-hexyl-1,5-pentanedioic acid 1-(L-leucine, N-phenylamide)amide,

u) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-butyl-1,5-pentanedioic acid 1-(L-leucine, N-phenylamide)amide,

v) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-(3-methylbenzyl)-1,5-pentanedioic acid 1-(L-leucine, N-phenylamide)amide,

w) 2(R)-(2-(4-(1-Propyl)phenyl)ethyl)-4-carboxy-1,9-nonanedioic acid 1-(L-leucine, N-methylamide)amide 9-phenylamide,

x) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-carboxy-1,9-nonanedioic acid 1-(L-leucine, N-methylamide)amide 9-tert-butylamide,

y) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-carboxy-1,9-nonanedioic acid 1-(L-leucine, N-methylamide)amide 9-benzylamide,

z) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-carboxy-1,9-nonanedioic acid 1-(L-leucine, N-methylamide)amide 9-(1(R)-phenylethyl)amide,

ab) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-carboxy-1,9-nonanedioic acid 1-(L-leucine, N-methylamide)amide 9-(1(S)-phenylethyl)amide,

ac) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-carboxy-1,9-nonanedioic acid 1-(L-leucine, N-methylamide)amide 9-(N-methyl-N-phenyl)amide,

ad) 2(R)-(2-(4-(1-Propyl)phenyl)ethyl)-4-carboxy-1,9-nonanedioic acid 1-(L-leucine, N-methylamide)amide,

ae) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-(4-benzoylamino-1-butyl)-1,5-pentan dioic acid 1-(L-leucine, N-methylamide)amide,

af) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-(4-phenylsulfonylamino-1-butyl)-1,5 -pentandioic acid 1-(L-leucine, N-methylamide)amide,

ag) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-(4-(N'-phenylureido)-1-butyl)-1,5-p entandioic acid 1-(L-leucine, N-methylamide)amide,

ah) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-(4-phenyloxycarbonyl-amino-1-butyl) -1,5-pentandioic acid 1-(L-leucine, N-methylamide)amide,

ai) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-(4-N'-benzyloxycarbonyl amino-L-prolylamino)-1-butyl)-1,5-pentandioic acid 1-(L-leucine, N-methylamide)amide,

aj) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-(4-(2-carboxybenzoylamino)-1-butyl) -1,5-pentandioic acid 1-(L-leucine, N-methylamide)amide, and

ak) 2(R)-(2-(4-(1-n-Propyl)phenyl)ethyl)-4-(4-cyano-1-butyl)-1,5-pentandioic a cid 1-(L-leucine, N-phenylamide)amide.

Summary for Patent: ⤷  Free Forever Trial

PCT Information
PCT FiledNovember 18, 1993PCT Application Number:PCT/US93/11207
PCT Publication Date:June 09, 1994PCT Publication Number:WO94/12169

Details for Patent 5,672,583

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04 ⤷  Free Forever Trial Merck & Co., Inc. (Rahway, NJ) 2014-09-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 5,672,583

Country Patent Number Estimated Expiration
Australia 5612994 ⤷  Free Forever Trial
Australia 679474 ⤷  Free Forever Trial
Canada 2149640 ⤷  Free Forever Trial
European Patent Office 0671911 ⤷  Free Forever Trial
Japan H08503475 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 9412169 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Mallinckrodt
Colorcon
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.